Somatostatin in peptic ulcer bleeding--results of a double-blind controlled trial. 1983

J P Galmiche, and J Cassigneul, and J Faivre, and J L Tranvouez, and D Ouvry, and R Colin, and J P Pascal, and C Klepping

The aim of this work was to assess the usefulness of somatostatin in acute peptic ulcer bleeding. Sixty-four patients with endoscopic evidence of duodenal ulcer bleeding completed a double-blind trial to compare the effectiveness of somatostain (6 mg i.v. per day) with that of placebo; incidence of treatment failure (i.e., rebleeding or persistent haemorrhage) was not different in the somatostatin and in the placebo groups (respectively 24% and 23%). Because the efficacy of cimetidine had previously been demonstrated in gastric ulcer bleeding, somatostatin was tested against cimetidine (1.6 g per day) in 50 patients with gastric ulcer haemorrhage. The treatment failed to control bleeding in 15% of somatostatin and in 17% of cimetidine treated subjects (n.s.). Both treatments were well tolerated and blood requirements were not different in the trial groups. These results show that the efficacy of somatostain in peptic ulcer bleeding is not different from placebo in duodenal ulcers and not different from cimetidine in gastric ulcers.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010438 Peptic Ulcer Hemorrhage Bleeding from a PEPTIC ULCER that can be located in any segment of the GASTROINTESTINAL TRACT. Hemorrhage, Peptic Ulcer,Peptic Ulcer Hemorrhages,Ulcer Hemorrhage, Peptic
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J P Galmiche, and J Cassigneul, and J Faivre, and J L Tranvouez, and D Ouvry, and R Colin, and J P Pascal, and C Klepping
July 1980, Lancet (London, England),
J P Galmiche, and J Cassigneul, and J Faivre, and J L Tranvouez, and D Ouvry, and R Colin, and J P Pascal, and C Klepping
October 1980, Lancet (London, England),
J P Galmiche, and J Cassigneul, and J Faivre, and J L Tranvouez, and D Ouvry, and R Colin, and J P Pascal, and C Klepping
September 1989, Gastroenterology,
J P Galmiche, and J Cassigneul, and J Faivre, and J L Tranvouez, and D Ouvry, and R Colin, and J P Pascal, and C Klepping
October 1985, British medical journal (Clinical research ed.),
J P Galmiche, and J Cassigneul, and J Faivre, and J L Tranvouez, and D Ouvry, and R Colin, and J P Pascal, and C Klepping
November 1985, British medical journal (Clinical research ed.),
J P Galmiche, and J Cassigneul, and J Faivre, and J L Tranvouez, and D Ouvry, and R Colin, and J P Pascal, and C Klepping
November 1970, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
J P Galmiche, and J Cassigneul, and J Faivre, and J L Tranvouez, and D Ouvry, and R Colin, and J P Pascal, and C Klepping
October 1978, Gastroenterologie clinique et biologique,
J P Galmiche, and J Cassigneul, and J Faivre, and J L Tranvouez, and D Ouvry, and R Colin, and J P Pascal, and C Klepping
September 1986, The Australian and New Zealand journal of surgery,
J P Galmiche, and J Cassigneul, and J Faivre, and J L Tranvouez, and D Ouvry, and R Colin, and J P Pascal, and C Klepping
April 1980, Lancet (London, England),
J P Galmiche, and J Cassigneul, and J Faivre, and J L Tranvouez, and D Ouvry, and R Colin, and J P Pascal, and C Klepping
May 1985, Lancet (London, England),
Copied contents to your clipboard!